Liquidia Informe acción MUN:LT4 Capitalización de mercado
€852.6m
Finanzas de la empresa + 10 Analistas
Liquidia Corporation
Informe acción MUN:LT4
Capitalización de mercado: €852.6m
Resumen de acción LT4 Liquidia Corporation, empresa biofarmacéutica, desarrolla, fabrica y comercializa diversos productos para necesidades no cubiertas de los pacientes en Estados Unidos.
Recompensas Análisis de riesgos Ver todos los controles de riesgos Competidores de Liquidia Corporation Historial de precios y rendimiento
Resumen de todos los máximos históricos, cambios y caídas de precios de Liquidia Precios históricos de las acciones Precio actual de la acción US$10.13 Máximo en las últimas 52 semanas US$15.62 Mínimo de 52 semanas US$5.87 Beta 0.20 1Cambio en 1 mes 9.45% Variación en 3 meses n/a Cambio de 1 año 72.57% 3Variación en 3 años 198.12% Variación en 5 años n/a Variación desde la OPV -17.37%
Noticias y actualizaciones recientes
Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024 Nov 04
Insufficient new directors Oct 03
Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting Oct 01 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Sep 11
Ver más actualizaciones
Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024 Nov 04
Insufficient new directors Oct 03
Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting Oct 01 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Sep 11
No longer forecast to breakeven Aug 28
Insufficient new directors Aug 28
Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD Aug 22
Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Aug 19
Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch Jun 05
First quarter 2024 earnings released: US$0.54 loss per share (vs US$0.18 loss in 1Q 2023) May 15
New minor risk - Profitability May 14
No longer forecast to breakeven May 14
Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024 May 09
Liquidia Corporation, Annual General Meeting, Jun 20, 2024 May 01
Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder Apr 02
CEO & Director recently sold €416k worth of stock Mar 21
Full year 2023 earnings released: US$1.21 loss per share (vs US$0.67 loss in FY 2022) Mar 14
Insufficient new directors Mar 07
Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024 Mar 07
Insufficient new directors Jan 25
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder Jan 25
Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder Jan 20
Liquidia Corporation Announces Updates to Operations Leadership Jan 19 Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP Jan 05
Insufficient new directors Jan 02
Forecast to breakeven in 2026 Dec 31
Independent Director recently bought €1.8m worth of stock Dec 22 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million. Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.14 loss in 3Q 2022) Nov 11
Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label Sep 26
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office Sep 08
Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder Jul 28
Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation Jul 25
Liquidia Corporation to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
CEO & Director recently bought €246k worth of stock Sep 09 Liquidia Corporation Provides Update on Hatch-Waxman Litigation
High number of new directors Aug 30 Rentabilidad de los accionistas LT4 DE Pharmaceuticals Mercado DE 7D 0% -0.9% 1.1% 1Y 72.6% -14.1% 13.5%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: LT4 superó a la industria German Pharmaceuticals, que obtuvo un rendimiento del -14.1% el año pasado.
Rentabilidad vs. Mercado: LT4 superó al mercado German, que obtuvo un rendimiento del 13.5% el año pasado.
Volatilidad de los precios Is LT4's price volatile compared to industry and market? LT4 volatility LT4 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 7.9% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: El precio de las acciones de LT4 ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de LT4 en el último año.
Acerca de la empresa Liquidia Corporation, empresa biofarmacéutica, desarrolla, fabrica y comercializa diversos productos para satisfacer necesidades no cubiertas de los pacientes en Estados Unidos. Entre sus principales productos candidatos figura YUTREPIA, una formulación en polvo seco inhalado de treprostinil para el tratamiento de la hipertensión arterial pulmonar (HAP) y la hipertensión pulmonar asociada a enfermedad pulmonar intersticial (PH-ILD). La empresa también ofrece Remodulin, un treprostinil administrado mediante infusión intravenosa y subcutánea continua.
Mostrar más Resumen de fundamentos de Liquidia Corporation ¿Cómo se comparan los beneficios e ingresos de Liquidia con su capitalización de mercado? Estadísticas fundamentales de LT4 Capitalización bursátil €852.59m Beneficios(TTM ) -€105.57m Ingresos (TTM ) €13.97m
61.0x Ratio precio-ventas (PS)
-8.1x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de LT4 Ingresos US$14.84m Coste de los ingresos US$4.52m Beneficio bruto US$10.32m Otros gastos US$122.43m Beneficios -US$112.11m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
Nov 13, 2024
Beneficios por acción (BPA) -1.33 Margen bruto 69.52% Margen de beneficio neto -755.46% Ratio deuda/patrimonio 137.0%
¿Cómo se ha desempeñado LT4 a largo plazo?
Ver rendimiento histórico y comparativa
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
